Interestingly, in the same cohort, FoxO3a and integrin α5 co-expression strongly improve DMFS (log-rank test, p = 0.0026, Figure 5c) compared to FoxO3a alone (log-rank test, p = 0.02, Appendix D, Figure A4a), corroborating the hypothesis that integrin α5 could emphasize FoxO3a protective role in ERα+ BC patients. Here, FOXO3 is linked to breast cancer.